Concurrent chemoradiotherapy with weekly docetaxel versus cisplatin in the treatment of locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis

Table 3 Chemoradiotherapy-related acute adverse events in the matched cohort

Adverse event	Docetaxel group [cases (%)]		Cisplatin group [cases (%)]		P value
Adverse event	Grade 1–2	Grade 3	Grade 1–2	Grade 3	P value
Leucopenia	90 (40.2)	5 (2.2)	164 (73.2)	26 (11.6)	< 0.001
Anemia	55 (24.6)	0	105 (46.8)	2 (0.9)	< 0.001
Thrombocytopenia	3 (1.3)	0	41 (18.3)	4 (1.8)	< 0.001
ALT elevation	42 (18.8)	1 (0.4)	68 (30.4)	2 (0.9)	0.027
CCR elevation	4 (1.8)	0	33 (14.7)	1 (0.4)	< 0.001
Vomiting^a	42 (18.8)	0	185 (82.5)	13 (5.8)	< 0.001
Mucositis^a	45 (20.1)	167 (74.5)	102 (45.5)	85 (37.9)	< 0.001
Weight loss^a	171 (76.3)	0	166 (74.1)	2 (0.1)	0.010
Radiodermatitis^a	191 (85.3)	15 (6.7)	185 (82.6)	4 (1.8)	0.001
Tinnitus^a	23 (10.3)	0	24 (10.7)	0	0.835
Xerostomia^a	171 (76.3)	2 (0.1)	170 (75.9)	2 (0.1)	0.052

Only one patient in the cisplatin group had grade 4 radiodermatitis
ALT Alanine transaminase, AST aspartate aminotransferase, CCR creatinine clearance
^aMissing value: In the docetaxel group, medical records of 10 patients were missing for radiodermatitis, mucositis, and xerostomia, 8 for vomiting, 6 for weight loss, and 12 for tinnitus; In the cisplatin group, medical records of 35 patients were missing for radiodermatitis, 37 for mucositis, 38 for xerostomia, 9 for vomiting, 17 for weight loss, and 38 for tinnitus

ISSN: 2523-3548